ZIM
TRVI icon

Zacks Investment Management’s Trevi Therapeutics TRVI Stock Holding History

Zacks Investment Management’s Portfolio TRVI Stock Details TRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-10,000
Closed -$23.9K – 707
2023
Q2 		$23.9K Buy
+10,000
New +$25.2K ﹤0.01% 634

Other funds holding TRVI

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return

Zacks Investment Management's TRVI Position: Q3 2023 in Review

Zacks Investment Management sold out of Trevi Therapeutics (TRVI) in Q3 2023, closing a stake of 10,000 shares — an estimated $23.9K sold.

Zacks Investment Management first reported a position in TRVI in Q2 2023 and held it in 1 quarter. The position peaked at $23.9K in Q2 2023. 55 funds tracked by Wall St. Rank hold TRVI as of Q3 2023.

  • Zacks Investment Management reported no remaining Trevi Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Zacks Investment Management sold 10,000 Trevi Therapeutics shares in Q3 2023, an estimated $23.9K.
  • Zacks Investment Management first reported a position in Trevi Therapeutics in Q2 2023 and held it in 1 quarter.
  • Zacks Investment Management's Trevi Therapeutics position peaked at $23.9K in Q2 2023.
  • 55 funds tracked by Wall St. Rank held Trevi Therapeutics as of Q3 2023.

Based on Zacks Investment Management's 13F filing for Q3 2023, filed 14 Nov 2023.